Implications of Expanding Use of CAR T-Cell Therapy in Relapsed/Refractory Non-Hodgkin Lymphoma (NHL)

Video

A discussion on the clinical impact of chimeric antigen receptor (CAR) T-cell therapy in relapsed/refractor (R/R) non-Hodgkin lymphoma and the role of expanding CAR T administration into the community practice setting.

Related Videos
Faraz Ali, MBA, the chief executive officer of Tenaya Therapeutics
Evan Weber, PhD, an assistant professor of pediatrics at Children's Hospital of Philadelphia
Faraz Ali, MBA, the chief executive officer of Tenaya Therapeutics
Shankar Ramaswamy, MD, the cofounder, chairman, and CEO of Kriya Therapeutics
Kevin Campbell, PhD, a Howard Hughes Investigator at the University of Iowa
Debora Mazzetti, MS, on Multitargeting MicroRNA in Glioblastoma
Abhishek Gupta, BS, the senior vice president of genetic medicines at Syneos Health
Francesca Del Bufalo, MD, PhD, a medical doctor and scientist at Bambino Gesù Chidren’s Hospital
Luke Roberts, MBBS, PhD, on Early Clinical Data on Congestive Heart Failure Gene Therapy
Lawrence R. Lustig, MD, the chair of the Department of Otolaryngology—Head and Neck Surgery at Columbia University College of Physicians
Related Content
Harish Venkatesh, BS candidate, Department of Regulatory and Quality Sciences, University of Southern California, Los Angeles, California

Cell and Gene Therapy Trials Face Disproportionate Amount of Clinical Holds

May 17th 2024
Article

Oncological trials of biologics also face particularly higher rates of clinical holds.

CGTLive®’s Weekly Rewind

CGTLive®’s Weekly Rewind – May 17, 2024

May 17th 2024
Article

Review top news and interview highlights from the week ending May 17, 2024.

Next ACGT Grant to Focus on Cell and Gene Therapy for Pancreatic Cancer

Next ACGT Grant to Focus on Cell and Gene Therapy for Pancreatic Cancer

May 17th 2024
Article

The invitation-only annual scientific summit, held on March 29, in New York City, brought together top scientists in cancer cell and gene therapy.

Verismo Therapeutics’ CAR-T SynKIR-310 Cleared for Trial in R/R B-NHL

Verismo Therapeutics’ CAR-T SynKIR-310 Cleared for Trial in R/R B-NHL

May 16th 2024
Article

Verismo intends to go forward with plans for the phase 1 CELESTIAL-301 clinical trial, which the company expects to initiate in the second half of this year.

Liso-Cel/Breyanzi Gets Accelerated Approval for Relapsed/Refractory Follicular Lymphoma

Liso-Cel/Breyanzi Gets Accelerated Approval for Relapsed/Refractory Follicular Lymphoma

May 16th 2024
Article

The CAR T-cell therapy was also recently approved for treating chronic lymphocytic leukemia or small lymphocytic lymphoma.

Around the Helix: Cell and Gene Therapy Company Updates – May 15, 2024

Around the Helix: Cell and Gene Therapy Company Updates – May 15, 2024

May 15th 2024
Article

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

© 2024 MJH Life Sciences

All rights reserved.